What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
0.9% isotonic sodium-chloride reconstitution diluent
PeptideXpo buyer fit
This PeptideXpo page is intentionally positioned for distributors, OEM buyers, and procurement teams comparing Saline (0.9% Sodium Chloride Injection) inside a wider peptide catalog. It is not trying to be the deepest single-molecule monograph; the differentiated intent is assortment planning, export-ready documentation, fill-size comparison, and whether this SKU belongs in a broader buyer program.
Overview
0.9% Sodium Chloride Injection (isotonic saline) is the standard isotonic reconstitution diluent for peptide preparations where neutral-pH and physiological osmolarity are appropriate. The 0.9% NaCl concentration produces a solution isotonic with blood plasma (≈300 mOsm/L), which minimizes osmotic stress when the reconstituted material is administered to cell-culture systems or in vivo. Saline is the workhorse diluent for the majority of peptide reconstitution workflows where the peptide is soluble and stable at neutral pH, this includes most synthetic peptides without aggregation tendency, in contrast to peptides like IGF-1 LR3 that require acidic-pH diluents instead. PeptideXpo supplies 0.9% Saline in 3 ml and 10 ml sterile vial formats, prepared from pharmaceutical-grade sodium chloride and Water for Injection. The release packet specifies sterility, bacterial endotoxin (LAL), osmolality, and pH per pharmacopeia standards.
Who buys this, and why
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Primary buyer fit: 503A / 503B compounding pharmacies, academic and contract research laboratories, and regional distributors and re-sellers.
Specifications
Documentation available on request
Regulatory note
Isotonic reconstitution diluent. Verify sterility, pyrogen (LAL), osmolality, and injectable-grade compliance with target market regulations.
Frequently asked questions
The 0.9% NaCl concentration (corresponding to ≈300 mOsm/L osmolality) matches the osmolality of normal blood plasma and extracellular fluid. Isotonic preparations don't drive net water movement across cell membranes when administered systemically, avoiding the hemolysis (in hypotonic preparations) or cell-shrinkage (in hypertonic preparations) that would occur with mismatched osmolality. For peptide reconstitution, isotonic saline produces working solutions that are physiologically compatible with both in vivo administration and most cell-culture-assay buffers. For peptides requiring acidic pH, isotonic saline is not appropriate, the 0.6% Acetic Acid Water diluent is the alternative; for sterile single-use preparations, preservative-free SWFI is preferred.
0.9% Sodium Chloride Injection is monographed in major pharmacopeias including USP (US Pharmacopeia), EP (European Pharmacopeia), BP (British Pharmacopeia), and JP (Japanese Pharmacopeia). The specifications cover identity (sodium and chloride content), sterility, bacterial endotoxins (LAL test, typically ≤0.5 EU/mL for IV-grade material), pH (typically 4.5-7.0), particulate matter, and osmolality (typically 286-313 mOsm/L for the 0.9% concentration). PeptideXpo's saline diluent is supplied to meet the USP monograph by default; buyers in EU, UK, or APAC markets requiring the local pharmacopeia spec should specify at quote stage so the released-batch documentation references the appropriate monograph.
Related peptides
